ArticleBMC oral health2026
The association between preoperative serum transferrin and occult metastasis in early T classification oral squamous cell carcinoma.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThis study aimed to investigate the potential of preoperative serum transferrin levels as a biomarker for predicting occult metastasis in patients with clinically node-negative (cN0), early T-classification (T1-T2) oral squamous cell carcinoma (OSCC).
methodsThis retrospective cohort study included 386 eligible patients with cN0 early-stage OSCC who underwent primary tumor resection and elective neck dissection at the Second Xiangya Hospital, Changsha, China. Preoperative serum transferrin levels were measured, and their association with occult metastasis (determined by postoperative pathology) was analyzed. Statistical analyses included univariate and multivariable logistic regression, restricted cubic spline (RCS) analysis for nonlinear relationships, subgroup analyses, and predictive performance metrics (AUC, calibration, decision curve analysis).
resultsOccult metastasis was identified in 104 patients (26.9%). Serum transferrin levels did not differ significantly between patients with and without metastasis (2.16 ± 0.37 vs. 2.14 ± 0.35 g/L, P = 0.693). On multivariable analysis, transferrin was not associated with occult metastasis (P > 0.05), whereas T classification and poorly differentiated histology emerged as significant predictors. RCS analysis confirmed a linear, non-significant relationship. None of the 27 subgroups showed significant differences. Adding transferrin to the baseline model did not improve AUC (unchanged at 0.637), net benefit, or calibration.
conclusionsPreoperative serum transferrin level was not associated with occult metastasis in early-stage, cN0 OSCC. Tumor-related factors, specifically differentiation grade and T classification, remained the primary predictors of metastatic risk. Serum transferrin does not appear to be a useful independent biomarker for preoperative metastasis risk stratification in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.